References
- BurgelPRNesme-MeyerPChanezPInitiatives Bronchopneumopathie Chronique Obstructive Scientific CommitteeCough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjectsChest2009135497598219017866
- VestboJPrescottELangePAssociation of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study GroupAm J Respir Crit Care Med19961535153015358630597
- DajaniRZhangYTaftPJLysozyme secretion by submucosal glands protects the airway from bacterial infectionAm J Respir Cell Mol Biol200532654855215746432
- EllisonRT3rdGiehlTJKilling of gram-negative bacteria by lactoferrin and lysozymeJ Clin Invest1991884108010911918365
- GordonLIDouglasSDKayNEYamadaOOssermanEFJacobHSModulation of neutrophil function by lysozyme. Potential negative feedback system of inflammationJ Clin Invest1979641226232221543
- ShimizuKKondoMYonebayashiSSakumaYTairaYEffects of lysozyme chloride (Acdeam®) on foreign materials excretion by tracheal mucociliary transportJpn Pharmacol Ther199725923472358
- KayamaSFukuchiYHarasawaMAn experimental study in the influence of age various drugs on ciliary beat frequencyJpn Pharmacol Ther1985132701705
- TanakaKMikamiMIshikawaTThe study of lysozyme chloride on the relationship between the chances of symptoms and physiochemical properties of sputum in chronic pulmonary diseaseJpn J Med Pharm Sci2005535581600
- OhbayashiHSetoguchiYFukuchiYShibataKSakataYAraiTPharmacological effects of lysozyme on COPD and bronchial asthma with sputum: a randomized, placebo-controlled, cross-over studyPulm Pharmacol Ther201637738026952317
- ZhengJPKangJHuangSGEffect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled studyLancet200837196292013201818555912
- ZhengJPWenFQBaiCXPANTHEON Study GroupTwice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trialLancet Respir Med20142318719424621680
- TsudaTSuematsuRKamoharaKDevelopment of the Japanese version of the COPD assessment testRespir Investig20125023439
- AgustiAThe path to personalised medicine in COPDThorax201469985786424781218
- AnthonisenNRManfredaJWarrenCPHershfieldESHardingGKNelsonNAAntibiotic therapy in exacerbation of chronic obstructive pulmonary diseaseAnn Intern Med198710621962043492164
- NaitoSTominagaHUnoJDohiguchiYHamaguchiKThe anti-inflammatory effect of lysozyme hydrochloride on rabbits with different dosesJpn Pharmacol Ther198614641654169
- FukawaKIrinoOWatanabeAPharmacological effects of lysozyme and its reaction with serum proteinsPharmacometrics1981214587593
- PiattiGAmbrosettiUSantusPAllegraLEffects of salmeterol on cilia and mucus in COPD and pneumonia patientsPharmacol Res200551216516815629263
- HoggJChuFUtokaparchSThe nature of small-airway obstruction in chronic obstructive pulmonary diseaseN Engl J Med2004350262645265315215480
- NishimuraMMakitaHNagaiKHokkaido COPD Cohort Study InvestigatorsAnnual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20121851445222016444
- CelliBRDecramerMWedzichaJAATS/ERS Task Force for COPDAn official American Thoracic Society/European Respiratory Society statement: research questions in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20151917e4e2725830527
- CazzolaMHananiaNAMacNeeWRüdellKHackfordCTamimiNA review of the most common patient-reported outcomes in COPD – revisiting current knowledge and estimating future challengesInt J Chron Obstruct Pulmon Dis20151072573825897216
- KonSSCanavanJLJonesSEMinimum clinically important difference for the COPD assessment test: a prospective analysisLancet Respir Med20142319520324621681
- HashidaSIshikawaENakamichiNSekinoHConcentration of egg white lysozyme in the serum of healthy subjects after oral administrationClin Exp Pharmacol Physiol2002291–2798311906463